Skip to content Skip to footer
Subscribe Now
NEWS

Philips Unveils Verida to Improve Diagnostic Imaging

Shots: Royal Philips has launched Verida, a detector-based spectral CT fully powered by AI, at RSNA 2025, with availability in select markets beginning in 2026 Verida integrates AI across the entire imaging chain to deliver high-quality spectral & high-definition images with minimal noise, while enabling significant dose reductions & reducing energy use by ~45% Verida reconstructs…
2 days ago

Read more

NEWS

Neuraxpharm and mjn-neuro to launch Episeras for Early Detection of Epileptic Seizures

Shots: Neuraxpharm & mjn-neuro will launch Episeras for real-time early seizure detection in ambulatory & homecare settings, with EU rollout planned for the H2’26 EPISERAS is being evaluated in the ongoing multicentre SERAS-Home_RWD study across Spain, the UK, & Germany, with interim data currently in preparation for publication Episeras is a non-invasive device that monitors…
November 27, 2025

Read more

Intelerad
NEWS

GE HealthCare to Acquire Intelerad for $2.3B

Shots: GE HealthCare has entered into an agreement to acquire Intelerad, expanding its cloud-enabled & AI-powered solutions portfolio As per the deal, GE HealthCare will acquire Intelerad for a purchase price of $2.3B in cash; closing is expected in H1’26 Acquisition will add Intelerad’s cloud-enabled radiology & cardiology imaging platforms & outpatient enterprise workflow solutions…
November 21, 2025

Read more

NEWS

Doc.com Launches AI & Blockchain Telemedicine Platform in the US

Shots: Doc.com launches its AI & blockchain-powered telemedicine platform in the US to improve patient access, data security, & care coordination Pts can securely connect with licensed in-state healthcare providers via mobile using the platform, with up to 15min. of complimentary teleconsultation offered during launch, available in eligible jurisdictions & subject to applicable regulations, followed…
November 12, 2025

Read more

NEWS

Ailux Collaborates with Eli Lilly to Accelerate Bispecific Antibody Development

Shots: Ailux (XtalPi’s subsidiary) has entered into a strategic platform-based collaboration with Eli Lilly to accelerate the discovery & development of bispecific antibodies (bsAbs) for various diseases As per the deal, Lilly will nominate an undisclosed number of target pairs for bsAb design & may license Ailux’s platform for internal use. In exchange, Ailux will…
November 6, 2025

Read more

NEWS

Manifold Bio Partners with Roche to Develop BBB shuttles for Neurological and Neurodegenerative Diseases

Shots: Manifold has entered into a strategic research collaboration & licensing deal with Roche to develop multiple next-gen blood-brain barrier (BBB) shuttles for neurological & neurodegenerative diseases, leveraging Manifold’s shuttle portfolio & mDesign AI-driven in vivo discovery platform As per the deal, Manifold will lead research & discovery of BBB shuttles for Roche’s therapeutic payloads,…
November 4, 2025

Read more

NEWS

Vara Reports CE Mark Approval of its Breast Imaging AI for Independent Second Reading of Mammography

Shots: Vara has received the European CE Mark approval for its breast imaging AI to operate as an independent second reader for both screening & diagnostic use, with EU availability starting Oct 15, 2025 Breast imaging AI was evaluated in the PRAIM study of 460,000 women across Germany, which demonstrated significant improvements in cancer detection &…
October 15, 2025

Read more

NEWS

insitro and Bristol Myers Squibb Collaborate to Advance Drug Discovery for Amyotrophic Lateral Sclerosis (ALS)

Shots: insitro & BMS have extended their 5yr. collaboration (2020) to discover novel small molecule therapies for ALS using insitro’s AI-enabled ChemML platform The 1yr. extension will focus on developing therapies for a novel ALS target identified preclinically, with insitro receiving ~$20M in new funding & remaining eligible for discovery, development, regulatory, & commercial milestones…
October 15, 2025

Read more

NEWS

Nabla Bio Collaborates with Takeda to Advance AI-Driven Protein Therapeutics Design

Shots: Nabla Bio has entered into a multi-year research collaboration with Takeda to advance AI-driven design of protein therapeutics, leveraging Nabla Bio’s Joint Atomic Model (JAM) Nabla Bio will deploy its proprietary JAM platform across Takeda’s early-stage programs to enable de novo antibody design for multiple targets, multi-specifics, challenging targets, & custom therapeutics As per the…
October 14, 2025

Read more

Load more